Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TGN-1412 monoclonal antibody

Known as: TGN 1412, monoclonal antibody TGN1412, TAB08 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
CD28 superagonists (CD28SAs) are potent T‐cell‐activating monoclonal antibodies (mAbs). In contrast to their benign behavior and… Expand
Highly Cited
2013
Highly Cited
2013
The failure of regulatory science to keep pace with and support the development of new biological medicines was very publically… Expand
Highly Cited
2011
Highly Cited
2011
Human volunteers receiving TGN1412, a humanized CD28-specific monoclonal antibody, experienced a life-threatening cytokine… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2010
Highly Cited
2010
BACKGROUND AND PURPOSE In 2006, a life‐threatening ‘cytokine storm’, not predicted by pre‐clinical safety testing, rapidly… Expand
Highly Cited
2010
Highly Cited
2010
TGN1412 is a "superagonistic" CD28 monoclonal antibody (IgG4) that caused serious adverse events at its first time in human… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2007
Highly Cited
2007
The CD28-specific mAb TGN1412 rapidly caused a life-threatening “cytokine storm” in all six healthy volunteers in the Phase I… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2006
Highly Cited
2006
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2006
Highly Cited
2006
  • M. Goodyear
  • BMJ : British Medical Journal
  • 2006
  • Corpus ID: 32298471
This experience should foster an open culture in medical research 
2006
2006
CAMBRIDGE, U.K.-- On 13 March, six healthy volunteers in a clinical trial were injected with a "superagonist," a drug meant to… Expand